About

Spherium Biomed is a clinical-stage, biopharmaceutical portfolio company that sources its pipeline from academic sources. The company acts as an advanced project incubator with the ultimate goal of reaching a relevant value milestone in order to increase the chance of academic discoveries reaching the market.  The company applies its broad experience in drug development (from discovery to clinical and commercial stages) to deeply analyze the commercial potential of technologies. After defining the relevant gaps with respect to an ideal target product profile, the company derives a creative and cost-effective work plan to bring the project forward, and implements the plan with its own resources and the proactive coordination of external providers.

Spherium is privately owned; its major shareholders are its founders and key executives, and the Spanish pharmaceutical company Ferrer (www.ferrer.com). Its current portfolio includes four projects which will begin clinical efficacy trials before the end of 2016 and several first-in-class preclinical projects expected to show proof of concept during 2016-2017. The company is constantly looking for new opportunities addressing unmet clinical needs.

For more information please contact info@spheriumbiomed.com